ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019 Strengthened Balance

ADMA Biologics Reports First Quarter

2020 Financial Results and Highlights Recent Company Progress

Achieved First Quarter 2020 Total Revenues

of $10.2 Million, a 189% Increase Over First Quarter 2019

Strengthened Balance Sheet Through Successful

Completion of Underwritten Public Offering

Management to Host Conference Call and

Webcast Today at 4:30 p.m. ET

RAMSEY, NJ and BOCA RATON, FL -- May 6, 2020 -- ADMA

Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,

marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection

and for the prevention of certain infectious diseases, today reported financial results for the quarter ended March 31, 2020, ADMA's

first fiscal quarter, and provided an overview of recent progress and accomplishments.

"During the first quarter of 2020, we invested in our

supply-chain robustness strategy and continued to make progress with reinforcing and expanding our commercial infrastructure by

building out our salesforce and medical affairs teams, while generating encouraging year-over-year quarterly revenue growth,"

said Adam Grossman, ADMA's President and Chief Executive Officer. "I am extremely proud of the ADMA Biologics team

as they have risen to the challenge of navigating the Company through the COVID-19 pandemic while continuing to provide critical

immune globulin (IG) and hyperimmune globulin products that U.S. patients and physicians need. Due to our strong foundation, we

believe we are well-positioned to not only weather the current macroeconomic challenges, but to continue to execute on our future

growth plans. Most importantly, everyone at ADMA offers our immense gratitude to all of the healthcare personnel, first responders

and others working on the front lines during this pandemic."

2020 Outlook and Objectives Update

Mr. Grossman continued, "These three substantial objectives

and investments, including increased raw material plasma collection, expanded production capacity and aseptic filling capability,

are anticipated to change the forward-looking outlook for ADMA in many positive ways, including potentially lowering costs, improving

gross margins, providing more flexibility with a reduction to batch production cycle time and ultimately giving ADMA additional

end-to-end control previously reserved for only the largest plasma fractionators."

First Quarter 2020 and Recent Highlights

First Quarter 2020 Financial Results

Total revenues for the quarter ended March 31, 2020 were $10.2

million, compared to $3.5 million for the first quarter ended March 31, 2019, representing an increase of approximately $6.7 million,

or 189%. The increase is mainly due to increased sales and production throughput of our immunoglobulin products generated by our

Boca Facility manufacturing operations in 2020 totaling $6.4 million, and to a $0.3 million increase in plasma revenues generated

by our plasma collection facility in 2020 as compared to the same period of a year ago. Our revenues for the first quarter of 2020

as compared to the first quarter of 2019 were favorably impacted by the FDA approvals of BIVIGAM and ASCENIV on May 9, 2019 and

April 1, 2019, respectively, and by the manufacturing and supply agreement we entered into in January 2020 to produce and sell

intermediate fractions to a certain customer.

Consolidated net loss for the first quarter of 2020 was $19.2

million, or $(0.26) per basic and diluted share, compared to a consolidated net loss of $13.1 million, or $(0.28) per basic and

diluted share, for the first quarter of 2019. The increase in net loss of $6.2 million was primarily due to the increase in cost

of product revenue of approximately $7.4 million, which increase is mainly a result of the investment made for the production of

BIVIGAM's conformance lots at an increased plasma pool production scale, which pertains specifically to our planned capacity

expansion, as well as other production enhancement initiatives and supply chain investments at the Boca Facility. The increase

in net loss during the first quarter of 2020 is also attributable to higher selling, general and administrative expenses of $2.3

million, mainly due to increases in employee compensation expenses in support of our commercialization efforts, increased interest

expense of $1.2 million due to our accessing additional debt during the second quarter 2019, along with higher research and development

expenses of $0.7 million, primarily related to a study we commenced for ASCENIV to potentially extend its approved and labeled

expiration dating, partially offset by the increase in revenues. Included in the net loss for the first quarter of 2020 were non-cash

expenses of approximately $1.9 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.

At March 31, 2020, ADMA had cash and cash equivalents of $101.2

million and accounts receivable of $7.1 million, compared to cash and cash equivalents and accounts receivable of $26.8 million

and $3.5 million, respectively, at December 31, 2019. ADMA's net working capital as of March 31, 2020 was $151.6 million,

compared to $71.8 million as of December 31, 2019.

In February 2020, ADMA completed an underwritten public offering

of 27,025,000 shares of its common stock at a public offering price of $3.50 per share, resulting in net proceeds of $88.7 million.

Conference Call Information

ADMA will host a conference call today, Wednesday, May 6, 2020,

at 4:30 p.m. Eastern Time, to discuss the first quarter 2020 financial results and recent corporate updates. To access the conference

call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer

to conference ID 5339498. A live audio webcast of the call will be available under "Events & Webcasts" in the Investor

section of the Company's website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company's

website approximately two hours after the event.

About Primary Humoral Immunodeficiency

Primary humoral immunodeficiency (PI), also known as primary

immune deficiency disease (PIDD), is a class of inherited genetic disorders that causes an individual to have a deficient or absent

immune system. According to the World Health Organization, there are approximately 350 different genetic mutations encompassing

PI. Some disorders are present at birth or in early childhood and the disorders can affect anyone regardless of age or gender.

Some affect a single part of the immune system, others may affect one or more components of the system. PI patients are vulnerable

to infections and are more likely to suffer complications from these infections compared to individuals with a normal functioning

immune system. Because patients suffering from PI lack a properly functioning immune system, they typically receive monthly treatment

with polyclonal immune globulin products. Without this exogenous antibody replacement, these patients would remain vulnerable to

persistent and chronic infections. Initially thought to be very rare, it is now estimated that the prevalence of PI in the U.S.

is 1 in 1,200, which translates to approximately 250,000 people.

BIVIGAM (immune globulin intravenous, human - 10% liquid)

is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated

for the treatment of primary humoral immunodeficiency (PI), including, but not limited to the following group of genetic disorders:

X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency.

BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against

bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation

of concentrated human Immunoglobulin (IgG) antibodies.

ASCENIV (immune globulin intravenous, human - slra 10%

liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the FDA on April 1, 2019 and

is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD),

in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA's unique, patented plasma donor screening

methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested using the Company's

proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are

used by the body's immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease.

ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical

company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient

patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three

FDA approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases:

ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of primary humoral immunodeficiency

(PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis

B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products

at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA Bio Centers

subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma

for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human